Literature DB >> 10373715

Low molecular weight heparins in the cardiac catheterization laboratory.

G Montalescot1, M Cohen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10373715     DOI： 10.1023/a:1008943529597

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  21 in total

1.  Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor.

Authors:  Z Xiao; P Théroux
Journal:  Circulation       Date:  1998-01-27       Impact factor: 29.690

2.  Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)

Authors:  W Klein; A Buchwald; S E Hillis; S Monrad; G Sanz; A G Turpie; J van der Meer; E Olaisson; S Undeland; K Ludwig
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

3.  Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.

Authors:  J P Zidar
Journal:  Am J Cardiol       Date:  1998-09-10       Impact factor: 2.778

4.  Clinical and angiographic implications of coronary stenting in thrombus-containing lesions.

Authors:  F Alfonso; P Rodriguez; P Phillips; J Goicolea; R Hernández; M J Pérez-Vizcayno; A Fernández-Ortiz; J Segovia; C Bañuelos; P Aragoncillo; C Macaya
Journal:  J Am Coll Cardiol       Date:  1997-03-15       Impact factor: 24.094

5.  Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. Saphenous Vein De Novo Trial Investigators.

Authors:  M P Savage; J S Douglas; D L Fischman; C J Pepine; S B King; J A Werner; S R Bailey; P A Overlie; S H Fenton; J A Brinker; M B Leon; S Goldberg
Journal:  N Engl J Med       Date:  1997-09-11       Impact factor: 91.245

6.  Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. Primary Angioplasty in Myocardial Infarction Stent Pilot Trial Investigators.

Authors:  G W Stone; B R Brodie; J J Griffin; M C Morice; C Costantini; F G St Goar; P A Overlie; J J Popma; J McDonnell; D Jones; W W O'Neill; C L Grines
Journal:  J Am Coll Cardiol       Date:  1998-01       Impact factor: 24.094

7.  Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial.

Authors:  G Montalescot; F Philippe; A Ankri; E Vicaut; E Bearez; J E Poulard; D Carrie; D Flammang; A Dutoit; A Carayon; C Jardel; M Chevrot; J P Bastard; F Bigonzi; D Thomas
Journal:  Circulation       Date:  1998-07-28       Impact factor: 29.690

8.  Heparin inhibition of smooth muscle cell proliferation: a cellular site of action.

Authors:  C F Reilly; L M Fritze; R D Rosenberg
Journal:  J Cell Physiol       Date:  1986-10       Impact factor: 6.384

9.  Increased platelet responsiveness following coronary stenting. Heparin as a possible aetiological factor in stent thrombosis.

Authors:  C J Knight; M Panesar; D J Wilson; A Patrineli; N Chronos; C Wright; D Clarke; D Patel; K Fox; A H Goodall
Journal:  Eur Heart J       Date:  1998-08       Impact factor: 29.983

10.  Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade.

Authors: 
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321
View more
  1 in total

Review 1.  Unfractionated versus fractionated heparin for percutaneous coronary intervention.

Authors:  Heidar Arjomand; Satish K Surabhi; Marc Cohen
Journal:  Curr Cardiol Rep       Date:  2002-07       Impact factor: 2.931
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.